Mucosolvan Inhalacje (Ambroxol Hydrochloride)

Ambroxol, the active ingredient in Mucosolvan Inhalacje, is a mucolytic agent presented as an inhalation solution for respiratory use. It facilitates the breakdown and clearance of thick mucus in patients with acute or chronic bronchitis and other respiratory tract infections characterized by mucus hypersecretion.

GNH USA supplies Mucosolvan Inhalacje as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality across global markets through established distribution networks and efficiently.

Mucosolvan Inhalacje, an inhaled mucolytic, is used in conditions where excessive respiratory mucus impairs ventilation. - Acute bronchitis: helps loosen and clear thick sputum, improving cough effectiveness. - Chronic bronchitis: reduces mucus viscosity, facilitating expectoration and relieving airway obstruction. - Respiratory tract infections with mucus hypersecretion: enhances mucociliary clearance, supporting recovery.

Like all medicines, inhaled ambroxol can be associated with adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Cough: transient irritation of the airways. - Throat irritation or dryness. - Bronchospasm: mild, reversible narrowing of airways. - Nausea or upset stomach. - Altered taste sensation. - Headache.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, or angioedema. - Severe bronchospasm or respiratory distress. - Anaphylactic shock: rare but potentially life‑threatening. - Hepatic enzyme elevation.

When prescribing or using Mucosolvan Inhalacje, several precautions should be observed to ensure safe and effective therapy. - Assess airway reactivity: evaluate for asthma or COPD before initiating inhalation therapy. - Use with caution in patients with known bronchial hyperreactivity: monitor for bronchospasm. - Monitor for hypersensitivity: discontinue if rash, urticaria or angioedema develop. - Avoid in individuals with documented ambroxol allergy: contraindicated. - Adjust use in hepatic impairment: consider reduced dosing or close monitoring. - Store at room temperature: keep in original container, protect from moisture and light.

Ambroxol may interact with other medicines; awareness of these interactions helps optimise therapy.

Major Interactions (Avoid): - Antitussive agents (e.g., codeine): may counteract the mucolytic effect by suppressing cough. - Bronchoconstrictor drugs (e.g., inhaled β‑blockers): can increase risk of bronchospasm when combined.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ambroxol plasma levels. - CYP2D6 substrates (e.g., metoprolol): potential for altered metabolism. - Other mucolytics (e.g., N‑acetylcysteine): additive effect may increase gastrointestinal irritation. - Anticoagulants (e.g., warfarin): occasional reports of altered INR; monitor coagulation parameters.